oxymetazoline has been researched along with Facial Dermatoses in 4 studies
Oxymetazoline: A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251)
oxymetazoline : A member of the class of phenols that is 2,4-dimethylphenol which is substituted at positions 3 and 6 by 4,5-dihydro-1H-imidazol-2-ylmethyl and tert-butyl groups, respectively. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used (generally as the hydrochloride salt) to relieve nasal congestion.
Facial Dermatoses: Skin diseases involving the FACE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This long-term study demonstrated sustained safety, tolerability, and efficacy of oxymetazoline for moderate-to-severe persistent erythema of rosacea." | 9.27 | Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial. ( Ahluwalia, G; Alvandi, N; Baumann, L; Berk, DR; Draelos, ZD; Gold, MH; Grekin, SK; Kempers, SE; Robinson, DM; Weiss, RA; Weng, E, 2018) |
| "These findings support the use of oxymetazoline for the treatment of persistent facial erythema associated with rosacea." | 9.27 | Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea. ( Ahluwalia, G; Attar, M; DuBois, J; Kuang, AW, 2018) |
| "This long-term study demonstrated sustained safety, tolerability, and efficacy of oxymetazoline for moderate-to-severe persistent erythema of rosacea." | 5.27 | Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial. ( Ahluwalia, G; Alvandi, N; Baumann, L; Berk, DR; Draelos, ZD; Gold, MH; Grekin, SK; Kempers, SE; Robinson, DM; Weiss, RA; Weng, E, 2018) |
| "These findings support the use of oxymetazoline for the treatment of persistent facial erythema associated with rosacea." | 5.27 | Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea. ( Ahluwalia, G; Attar, M; DuBois, J; Kuang, AW, 2018) |
| "Rosacea is a common chronic facial dermatosis." | 2.61 | Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. ( Arents, BWM; Carter, B; Charland, L; Fedorowicz, Z; Tan, J; van der Linden, MMD; van Zuuren, EJ, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Draelos, ZD | 1 |
| Gold, MH | 2 |
| Weiss, RA | 1 |
| Baumann, L | 1 |
| Grekin, SK | 1 |
| Robinson, DM | 2 |
| Kempers, SE | 1 |
| Alvandi, N | 2 |
| Weng, E | 1 |
| Berk, DR | 2 |
| Ahluwalia, G | 3 |
| Kuang, AW | 1 |
| DuBois, J | 1 |
| Attar, M | 1 |
| Lebwohl, M | 1 |
| Biesman, BS | 1 |
| Luo, L | 1 |
| van Zuuren, EJ | 1 |
| Fedorowicz, Z | 1 |
| Tan, J | 1 |
| van der Linden, MMD | 1 |
| Arents, BWM | 1 |
| Carter, B | 1 |
| Charland, L | 1 |
1 review available for oxymetazoline and Facial Dermatoses
| Article | Year |
|---|---|
Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Bacterial Agents; Brimonidine Tartrate; Combin | 2019 |
3 trials available for oxymetazoline and Facial Dermatoses
| Article | Year |
|---|---|
Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Dose-Response Relationship, Drug; Drug Administration | 2018 |
Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adult; Aged; Dose-Response Relationship, Drug; D | 2018 |
Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Erythema; Facial Dermatoses; Humans; Oxymetazoline; Ro | 2018 |